FDA Nod for a “Truly Transformational” Melanoma Therapy
By Ted Rosen, MD The U.S. Food and Drug Administration (FDA) recently approved a truly transformational therapy, Lilileucel (Amtagvi,Iovance Biotherapeutics), designed for unresectable or metastatic malignant melanoma previously treated with other modalities. Prior failure of immune checkpoint inhibitors (PD-1 blocking antibodies) or of a BRAF inhibitor (with or without a concurrent MEK inhibitor) is a […]